This study will assess an investigational treatment for patients diagnosed with all three major types of Epidermylosis Bullosa (EB).

The ESSENCE Study is a Phase 3 clinical trial of SD-101, an investigational topical cream being developed by Amicus, together with Scioderm, to treat skin blistering and lesions associated with Epidermylosis Bullosa.

For more information:

 

Clinical Trial Overview

The ESSENCE Study is a Phase 3 clinical trial of SD-101, an investigational topical cream being developed by Amicus, together with Scioderm, to treat skin blistering and lesions associated with EB. The painful symptoms and burden of daily wound care make EB a devastating illness with a significant unmet need among patients and families.

more »

Participant Criteria

The ESSENCE Study is open to patients one month of age and older, who have a documented diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB. Participants must have a wound that meets specific study criteria as assessed by a healthcare professional.

more »

Study Locations

The ESSENCE Study is being conducted at sites in countries around the world, including sites in Europe and the United States. In the United States, the study will be conducted in various states from coast-to-coast. Additional locations are continually being added. Check the website or contact us for more details.

more »